

This item is the archived peer-reviewed author-version of:

The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients

Reference:

Massart Annick, Pallier Annaick, Pascual Julio, Viklicky Ondrej, Budde Klemens, Spasovski Goce, Klinger Marian, Sever Mehmet Sukru, Sorensen Soren Schwartz, Hadaya Karine,- The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients
Nephrology, dialysis, transplantation - ISSN 0931-0509 - 31:6(2016), p. 1002-1013
Full text (Publishers DOI): <http://dx.doi.org/doi:10.1093/NDT/GFV437>
To cite this reference: <http://hdl.handle.net/10067/1312480151162165141>

Original Article

The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients

Annick Massart^{1,2,*}, Annaïck Pallier^{3,*}, Julio Pascual⁴, Ondrej Viklicky⁵, Klemens Budde⁶, Goce Spasovski⁷, Marian Klinger⁸, Mehmet Sukru Sever⁹, Søren Schwartz Sørensen¹⁰, Karine Hadaya¹¹, Rainer Oberbauer¹², Christopher Dudley¹³, Johan W. De Fijter¹⁴, Alexander Yussim¹⁵, Marc Hazzan¹⁶, Thomas Wekerle¹⁷, David Berglund¹⁸, Consuelo De Biase¹⁹, María José Pérez-Sáez⁴, Anja Mühlfeld²⁰, Giuseppe Orlando²¹, Katia Clemente²², Quirino Lai²², Francesco Pisani²², Aljosa Kandus²³, Marije Baas²⁴, Frederike Bemelman²⁵, Jadranka Buturovic Ponikvar²³, Hakim Mazouz²⁶, Piero Stratta²⁷, Jean-François Subra²⁸, Florence Villemain²⁸, Andries Hoitsma²⁴, Laura Braun²⁹, Maria Carmen Cantarell³⁰, Hulya Colak³¹, Aisling Courtney³², Giovanni Maria Frasca³³, Matthew Howse³⁴, Maarten Naesens³⁵, Tomas Reischig³⁶, Daniel Serón³⁰, Nurhan Seyahi³⁷, Cem Tugmen³⁸, Angel Alonso Hernandez³⁹, Luboslav Beňa⁴⁰, Luigi Biancone⁴¹, Vania Cuna⁴², Carmen Díaz-Corte⁴³, Alexandre Dufay⁴⁴, André Gaasbeek⁴⁵, Arnaud Garnier⁴⁶, Philippe Gatault⁴⁷, Miguel Angel Gentil Govantes⁴⁸, François Glowacki⁴⁹, Oliver Gross⁵⁰, Bruno Hurault de Ligny⁵¹, Uyen Huynh-Do⁵², Bénédicte Janbon⁵³, Luis Antonio Jiménez del Cerro⁵⁴, Frieder Keller⁵⁵, Gaetano La Manna⁴², Ricardo Lauzurica⁵⁶, Hervé Le Monies De Sagazan⁴⁴, Friedrich Thaiss⁵⁷, Christophe Legendre⁵⁸, Séverine Martin⁵⁹, Marie-Christine Moal⁶⁰, Christian Noël⁴⁹, Evangeline Pillebout⁶¹, Gian Benedetto Piredda⁶², Ana Ramírez Puga⁶³, Wladyslaw Sulowicz⁶⁴, Serhan Tuglular⁶⁵, Michaela Prokopova⁵, Mélanie Chesneau⁶⁶, Alain Le Moine¹, Pierrick Guérif⁶⁶, Jean-Paul Soullillou^{3,66,68}, Marc Abramowicz⁶⁷, Magali Giral^{3,66,68}, Judith Racapé⁶⁹, Umberto Maggiore¹⁹, Sophie Brouard^{3,66,68,*} and Daniel Abramowicz^{70,71,*}

¹Renal Unit, CUB Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium, ²Medical Genetics Department, ULB, Brussels, Belgium, ³Joint Research Unit 1064, French Institute of Health and Medical Research, Nantes, France, ⁴Nephrology, Hospital del Mar, Barcelona, Spain, ⁵Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ⁶Nephrology, Charité Campus Mitte, Berlin, Germany, ⁷University Department of Nephrology, Skopje, Macedonia, ⁸Nephrology and Transplantation Medicine, Wrocław, Poland, ⁹Internal Medicine, Nephrology, Istanbul School of Medicine, Istanbul, Turkey, ¹⁰Nephrology P, Rigshospitalet, Copenhagen, Denmark, ¹¹Nephrology and Transplantation, Geneva University Hospitals, Geneva, Switzerland, ¹²Department of Medicine III–Nephrology, Hypertension and Renal Transplantation, Krankenhaus Elisabethinen Linz, Linz, Austria, ¹³Richard Bright Renal Centre, Southmead Hospital, North Bristol NHS Trust, Bristol, UK, ¹⁴Department of Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, The Netherlands, ¹⁵Department of Transplantation, Rabin Medical Center, Tel Aviv University Sackler School of Medicine, Tel Aviv, Israël, ¹⁶Nephrology Department, CHU Lille, Lille, France, ¹⁷Section of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, Austria, ¹⁸Department of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Sweden, ¹⁹UOS Trapianti

Rene Pancreas, Centro Trapianti di Parma, Az. Ospedaliero-Universitaria di Parma, Parma, Italy, ²⁰Department of Nephrology, University Hospital Aachen, Aachen, Germany, ²¹Wake Forest School of Medicine, Department of Surgery, Section of Transplantation, Winston-Salem, NC, USA, ²²U.O.C. Trapianti D'Organo, L'Aquila, Italy, ²³Department of Nephrology, Renal Transplantation Centre Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²⁴Kidney Diseases, Radboudumc Nijmegen, Nijmegen, The Netherlands, ²⁵Renal Transplant Unit, Department of Nephrology, Academic Medical Center, Amsterdam, The Netherlands, ²⁶Service de Néphrologie, Unité de Transplantation Rénale et Pancréatique, CHU Sud, Amiens, France, ²⁷Department of Translational Medicine, Amedeo Avogadro University, AOU Maggiore della Carità di Novara, Novara, Italy, ²⁸Service de Néphrologie-Dialyse-Transplantation, CHU Angers, Angers, France, ²⁹Hôpital de jour de Néphrologie, service de Néphrologie et Transplantation Rénale, Nouvel hôpital Civil, CHU de Strasbourg, Strasbourg, France, ³⁰Nephrology, Hospital Universitari Val d'Hebron, Barcelona, Spain, ³¹Nephrology, Tepecik Training and Research Hospital, Izmir, Turkey, ³²Regional Nephrology Unit, Belfast City Hospital, Belfast, UK, ³³Nefrologia, Dialisi e Trapianto di rene, AO Torrette Umberto I, Ancona, Italy, ³⁴Nephrology/Transplantation, Royal Liverpool University Hospital, Liverpool, UK, ³⁵Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium, ³⁶Nephrology Ward, Department of Internal Medicine, University Hospital Pilsen, Pilsen, Czech Republic, ³⁷Nephrology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, ³⁸General Surgery, Tepecik Training and Research Hospital, Yenisehir, Izmir, Turkey, ³⁹Servicio de Nefrología, Hospital Universitario, A Coruña, Spain, ⁴⁰Transplant Centre, University Hospital Louis Pasteur Kosice, Kosice, Slovakia, ⁴¹Department of Medical Sciences, University of Turin, Turin, Italy, ⁴²Department of Specialized, Experimental and Diagnostic Medicine, Section of Nephrology, Nephrology Dialysis and Renal Transplant Unit, St Orsola University Hospital, University of Bologna, Bologna, Italy, ⁴³Nephrology, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain, ⁴⁴Service Néphrologie, Hôpital Victor Provo, Roubaix, France, ⁴⁵Nierziekten, LUMC, Leiden, The Netherlands, ⁴⁶Néphrologie – Médecine Interne – Hypertension Pédiatrique, Hôpital des Enfants, Toulouse, France, ⁴⁷Service Néphrologie – Immunoclinique, CHRU, Hôpital Bretonneau, Tours, France, ⁴⁸Unidad de Gestión Clínica de Urología y Nefrología, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁴⁹Nephrology Department, University Hospital of Lille, Lille, France, ⁵⁰Department of Nephrology and Rheumatology, University Medicine Göttingen, Göttingen, Germany, ⁵¹Service de Néphrologie, CHRU Avenue Georges Clémenceau, Caen, France, ⁵²Division of Nephrology, Hypertension and Clinical Pharmacology, Inselspital, University Hospital Bern, Bern, Switzerland, ⁵³Transplantation rénale, CHU Grenoble, Grenoble, France, ⁵⁴Servicio de Nefrología, Hospital General Universitario de Alicante, Alicante, Spain, ⁵⁵Internal Medicine 1, Nephrology, University Hospital Ulm, Ulm, Germany, ⁵⁶Nephrology, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain, ⁵⁷University Hospital Hamburg Eppendorf (UKE), Hamburg, Germany, ⁵⁸Université Paris Descartes et Hôpital Necker, Paris, France, ⁵⁹Service d'hémodialyse et de Néphrologie, Hôpital Robert Boulin, Libourne, France, ⁶⁰Service de Néphrologie, CHRU de Brest, Brest, France, ⁶¹Nephrology Unit, Hôpital Saint Louis, Paris, France, ⁶²Kidney Diseases, Kidney Transplant Az. Osp. G. Brotzu, Cagliari, Italy, ⁶³Servicio de Nefrología, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ⁶⁴Department of Nephrology, University Hospital Krakow, Krakow, Poland, ⁶⁵Nephrology, Marmara School of Medicine Hastanesi, Istanbul, Turkey, ⁶⁶Institute of Transplantation Urology and Nephrology, Nantes University Hospital, Nantes, France, ⁶⁷Medical Genetics Department and IRIBHM (Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire), ULB, Brussels, Belgium, ⁶⁸Faculty of Medicine, Nantes University, Nantes, France, ⁶⁹Research Center of Epidemiology, Biostatistics and Clinical Research, School of Public Health, ULB, Brussels, Belgium, ⁷⁰Nephrology-Renal Transplantation Department, Universitair Ziekenhuis Antwerp, Antwerp, Belgium and ⁷¹Université Libre de Bruxelles (ULB), Brussels, Belgium

Correspondence and offprint requests to: Annick Massart; E-mail: annick.massart@ulb.ac.be

*Both first and both senior authors contributed equally to this work.

ABSTRACT

Background. Kidney recipients maintaining a prolonged allograft survival in the absence of immunosuppressive drugs and without evidence of rejection are supposed to be exceptional. The ERA-EDTA-DESCARTES working group together with Nantes University launched a European-wide survey to identify new patients, describe them and estimate their frequency for the first time.

Methods. Seventeen coordinators distributed a questionnaire in 256 transplant centres and 28 countries in order to report as many 'operationally tolerant' patients (TOL; defined as

having a serum creatinine <1.7 mg/dL and proteinuria <1 g/day or g/g creatinine despite at least 1 year without any immunosuppressive drug) and 'almost tolerant' patients (minimally immunosuppressed patients (MIS) receiving low-dose steroids) as possible. We reported their number and the total number of kidney transplants performed at each centre to calculate their frequency.

Results. One hundred and forty-seven questionnaires were returned and we identified 66 TOL (61 with complete data) and 34 MIS patients. Of the 61 TOL patients, 26 were previously described by the Nantes group and 35 new patients are presented here. Most of them were noncompliant patients. At data

collection, 31/35 patients were alive and 22/31 still operationally tolerant. For the remaining 9/31, 2 were restarted on immunosuppressive drugs and 7 had rising creatinine of whom 3 resumed dialysis. Considering all patients, 10-year death-censored graft survival post-immunosuppression weaning reached 85% in TOL patients and 100% in MIS patients. With 218 913 kidney recipients surveyed, cumulative incidences of operational tolerance and almost tolerance were estimated at 3 and 1.5 per 10 000 kidney recipients, respectively.

Conclusions. In kidney transplantation, operational tolerance and almost tolerance are infrequent findings associated with excellent long-term death-censored graft survival.

Keywords: frequency, graft survival, kidney transplantation, minimally immunosuppressed patients, operational tolerance

INTRODUCTION

The natural history of an untreated allograft in humans is graft rejection. Immunosuppressive drugs made organ transplantation possible but even the latest generation of these drugs carry the risk of major infectious [1], malignant [2] or metabolic [3] complications. Together with acute and chronic rejections, immunosuppression side effects heavily affect the long-term survival of both allografts and patients [4].

The induction of a tolerant state, intended as a selective acceptance of the allograft by the host immune system, was always a highly desirable goal in transplantation.

Despite outstanding successes [5, 6], induction of tolerance protocols remain risky and are not ready for clinical routine. Interestingly, a very limited number of organ recipients have been described as maintaining a prolonged allograft survival despite the accidental discontinuation of any immunosuppressive drugs [7–9]. Kidney recipients displaying operational tolerance may have withdrawn their immunosuppressive regimen of their own accord—by noncompliance—or may have been advised to do so by their nephrologist on the grounds of serious infections or malignancies [9]. This condition was termed as ‘clinical operational tolerance’ in reference to its spontaneous apparition.

The recently accepted definition of clinical operational tolerance is that of a good and stable graft function for at least 1 year after complete immunosuppression withdrawal [7, 8, 10]. This apparently unambitious definition contrasts with that of experimental tolerance. Aside from this criteria, laboratory animals must fulfil very stringent conditions to be declared tolerant including *in vitro* evidence that donor-specific responses are absent or suppressed and a normal histologic appearance of the transplanted allograft. Often, the demonstration that the donor recipient accepts a second graft from the same donor but rejects a third party graft is required [11]. In practice, physicians and patients—either compliant or not—are often reluctant to perform a biopsy of a well-functioning transplant. In practice, *in vitro* tests or validated surrogate biomarkers are not yet available and challenge transplantations would obviously be non-realistic and futile. As a consequence, the concept of operational tolerance permits a broader range of situations than the strict concept of experimental tolerance does [12].

Despite this minimalist definition, operational tolerance is distinctly rare in kidney transplantation [11, 13]. Indeed, <200 cases of tolerant kidney transplant recipients have been reported to date [7, 9, 10, 13–15] among more than half a million kidney transplants performed worldwide [16]. Several predictive biomarkers have been proposed [10, 15, 17–20] to detect or to predict operational tolerance after drug withdrawal, but none of them has been shown in prospective, controlled trials to allow safe immunosuppression withdrawal. This fact, along with the serious consequences of acute kidney rejection, refrained care providers from testing for tolerance by simply discontinuing immunosuppression, even in a stepwise manner [21]. Also, the exact frequency of operational tolerance among kidney recipients is unknown.

The ERA-EDTA-DESCARTES transplantation working group together with Nantes University (France) set up a European-wide survey to discover and describe new operationally tolerant kidney recipients and to evaluate the cumulative incidence of this phenotype. We aimed to identify new cohorts of operationally tolerant patients for further immunological and molecular studies.

MATERIALS AND METHODS

Survey

Seventeen national or regional coordinators from 28 European countries (Supplementary data, Table S1) sent a standardized questionnaire to 256 transplantation centres or centres offering transplantation consultations between 10 September 2013 and 12 November 2014. Centre investigators were asked to report anonymized data on operationally tolerant (TOL) and almost tolerant (minimally immunosuppressed, MIS) patients. Considering rare and, sometimes, transient conditions, we encouraged the report of every patient with a history of operational tolerance either active or past, alive or dead. Patient screening was performed according to each centre’s own resources through a computerized database or physician recollections. In parallel with the inventory of TOL patients, investigators were asked to report on the total number of kidney transplants ever performed at each centre. Finally, this survey included updated data from the 27 patients previously described by the Nantes group [9]. They were used for the calculation of cumulative incidence and for survival analysis.

Patients and controls

TOL patients were defined as allogeneic kidney recipients maintaining a good graft function—for working purposes, we chose the clear definition of a serum creatinine below <1.7 mg/dL and a proteinuria <1 g/day or g/g creatinine—for at least 1 year after complete immunosuppression withdrawal [7]. We identified 66 TOL patients of which 61 provided sufficient data to enter the complete analysis while 5 only contributed to the calculation of cumulative incidence.

MIS patients ($n = 34$) fulfilled the same criteria but were still receiving prednisone (or steroid equivalent) at a dose lower than 10 mg/day. Patients with higher creatinine and/or proteinuria but who maintained a stable graft function during at least 1

year without immunosuppression were also considered for analysis ($n = 4/61$ for TOL and $1/34$ for MIS). Since we know from previous studies [9, 14] that tolerant states could be transient only but also that those patients were probably rare and precious, we chose to report TOL and MIS patients whether prevalent or not, i.e. inclusive of patients no longer tolerant at the time of the report because of death, resumption of immunosuppressive drugs or declining graft function. Consequently, we also asked our collaborators to report on the full number of transplantations performed at their centre. Finally, we excluded patients in whom operational tolerance resulted from an intervention (e.g. allogeneic stem cell transplantation) or from a transplantation between monozygotic twins.

For comparison purposes, the TOL cohort ($n = 61$) was subdivided into 'new' ($n = 35$) and 'historical' TOL ($n = 26$) patients, for those previously described by the Nantes group [9].

Data collection

Data were collected using a standardized data form or updated (for Nantes historical TOL patients). The questionnaire included enquiries about recipient's demographics (sex, date of birth, past medical and renal history), donor characteristics (age, sex, living or deceased donors), immunological data [number of human leucocyte antigen (HLA) system mismatches, anti-HLA antibodies, Epstein-Barr virus (EBV) and cytomegalovirus (CMV) serological status], immunosuppression and tolerance periods (durations, outcomes and graft function). In addition, whenever necessary, the physicians who sent back the questionnaires were contacted by e-mail to complete all the required information. In cases of uncertainty regarding the exact month when operational tolerance started in the context of noncompliance, we arbitrarily chose a start date of 15 June of the first year of complete immunosuppression withdrawal.

Statistical analysis

Results from continuous variables with and without normal distribution were expressed as mean \pm standard deviation (SD) and median and interquartile range (IQR), respectively, and categorical data were expressed as percentages. TOL and MIS patients were compared by using Student's *t*-test for normally distributed data, Mann-Whitney *U*-test for non-normally distributed data and Fisher's exact test or χ^2 for categorical variables. Death-censored graft survival and patient survival analysis were performed for the whole TOL and MIS cohorts according to the Kaplan-Meier method. Statistical analyses were performed using STATA software, version 12 (StataCorp LP). Statistical significance was taken below the 5% level. *P*-values were calculated with full non-normalized data.

RESULTS

Cumulative incidence of operational tolerance and almost tolerance among kidney recipients

One hundred and forty-seven out of 256 questionnaires were returned reporting on a total of 218 913 transplants that were performed over a cumulative period of 3635 years. Sixty-six

eligible TOL and 34 MIS patients were identified (Figure 1). Overall, tolerance and almost tolerance were reported in 3 [95% confidence interval (CI): 2.64–3.37] and 1.5 (95% CI: 1.53–1.58) patients out of 10 000 kidney recipients, respectively.

Considering the higher frequency of TOL patients in France, we compared France with the remaining European countries: TOL patients were reported in 3.9 out of 10 000 kidney recipients in France versus 1.7 out of 10 000 outside France ($P = 0.07$).

Characteristics of the 35 new operationally tolerant patients

Important medical or administrative data were missing in 5 out of 66 patients entering the survey. Among the 61 patients with complete data, 26 have been described previously [9]. Thirty-five new TOL subjects are detailed here (see flow chart in Figure 2A and Table 1), of which 31 fulfilled the definition of good graft function as described above. The remaining four have displayed suboptimal (either serum creatinine or proteinuria above the limits) but stable function for at least 1 year without immunosuppressive therapy and also entered the study as TOL (patients referred to as 'T6, T9, T22 and T31' in Figure 3A). These 35 newly described patients were mainly males of European ancestry. Of note, glomerulonephritis/sclerosis or pyelonephritis was reported as primary renal disease in 51%, while diabetes or hypertension was reported in 6%. Patients ($n = 35$) were transplanted at a mean age of 29 ± 13 years. They received their first graft in 88% of cases after spending 17 (8–26) ($n = 26$) months on dialysis. Four patients out of 35 were pre-emptively transplanted. Donors were deceased in 60% of cases ($n = 21/35$), males in 70% ($n = 23/33$) and had a mean age of 33.5 ± 11 years. The cohort was composed of 25% ($n = 8/31$) full HLA-matched donor-recipient pairs. The remaining 23 patients had a mean number of HLA-A, -B and -DR mismatches of 2.8 ± 1 . One-quarter had a history of alloimmunization prior to transplantation, detected either by a complement-dependent cytotoxicity assay or by Luminex. Three out of 35 patients experienced an episode of biopsy-proven rejection before the period of immunosuppression discontinuation. Several patients ($n = 4/25$) developed CMV ($n = 2$) or EBV ($n = 2$) seroconversion under immunosuppression and four were diagnosed with malignancy (lymphoproliferative disease in three and multiple skin cancers in one). The median time passed off immunosuppression was 108 (58–156) months. The majority (90%) of the patients discontinued their immunosuppressive medications because of noncompliance, mental illness or social considerations. At the latest observation of tolerance, median creatininemia was 1.35 (1.1–1.48) mg/dL. Proteinuria exceeding 300 mg/day (but below 1 g/day) was noted in 9 out of 29 patients (31%).

Characteristics of minimally immunosuppressed patients

We identified 34 MIS patients (Table 1). Thirty-three fulfilled the definition of a good kidney function, while the remaining one presented a suboptimal (serum creatinine above the limit) but stable graft function for at least 1 year with 7.5 mg prednisone per day (patient referred to as 'M10' in Figure 3B). End-stage kidney disease resulted from either glomerulonephritis/




FIGURE 1: (A) Number of centres contacted (dashed bars) and questionnaires returned (white bars) per country, ordered by ascending number of questionnaires returned. (B) Cumulative incidences of TOL (black bars) and MIS (grey bars) patients reported per 10 000 kidney recipients per country. Countries were ordered by ascending number of combined TOL + MIS incidences.

sclerosis or pyelonephritis in 59% and from diabetes or hypertension in <3%. Dialysis duration was 25 (12–36) months for 27 patients while 2 were pre-emptively transplanted. One patient received a combined kidney–pancreas transplant. Mean donor age was 32 ± 14 years. Sixteen per cent of the donor–

recipient pairs were HLA complete matches ($n = 5/32$), while the others displayed an overall mean number of 3.2 ± 1 mismatches with 0.9 ± 0.7 mismatches at HLA-DR. Eleven patients out of 31 had evidence of HLA immunization prior to transplantation. Twenty-seven patients experienced 32 malignancies




FIGURE 2: (A) Flow chart and outcomes of TOL patients through the study. (B) Flow chart and outcomes of MIS patients through the study. IS, immunosuppressive.

under immunosuppression, mainly lymphoproliferative diseases ($n = 20$). This was the major reason for the physician-driven decision of immunosuppression weaning. At the latest observation of almost tolerance, mean creatininemia was 1.23 (0.96–1.5) mg/dL and 10 patients out of 32 (31.2%) displayed proteinuria above 300 mg/day (but below 1 g/day).

New operationally tolerant patients follow-up

Data on newly described TOL patients ($n = 35$) covered a median period of 191 (145–255) months post-transplantation. At the time of data capture (see flow chart in Figure 2A), a first group of 23 patients were still operationally tolerant after a median time of 79 (39–120) months without immunosuppression.

Table 1. Demographic data of tolerant and minimally immunosuppressed patients

	New TOL patients (N = 35)	Historic TOL patients (N = 26)	All TOL (N = 61)	MIS cohort (N = 34)	P-value for the comparison of all TOL versus MIS
Recipient features					
Age at transplantation date (years) ^a	29.1 ± 13	34.6 ± 16	31.5 ± 14	37.6 ± 14	0.05
Male gender	26 (74)	19 (73)	45 (74)	17 (90)	0.02
European origin	29 (83)	22 (88)	51 (85)	28 (90)	NS
Primary nephropathy					NS
According to ERA-EDTA classification					
Glomerulonephritis/sclerosis	11 (31)	13 (50)	24 (39)	14 (41)	
Pyelonephritis	7 (20)	4 (15)	11(18)	6 (18)	
Polycystic kidney disease	3 (9)	0	3 (5)	3 (9)	
Hypertension	1 (3)	0	1 (2)	0	
Renal vascular disease	0	0	0	1 (3)	
Diabetes	1 (3)	3 (11)	4 (7)	1 (3)	
Miscellaneous	7 (20)	4 (15)	7 (11)	5 (145)	
Unknown	5 (14)	2 (8)	7 (11)	4 (12)	
History of dialysis	28 (85)	20 (95)	48 (90)	32 (94)	NS
Dialysis vintage (months) (excluding zero) ^b	(n = 26) 17 (8–26)	(n = 19) 36 (17–63)	(n = 45) 24 (10–36)	(n = 32) 25 (12–36)	NS
History of auto-immune disease	3 (9)	5 (23)	8 (14)	4 (12)	NS
History of cancer before transplantation period	2 (6)	2 (8)	4 (7)	1 (3)	NS
Transplantation features					
Donor age (years) ^a	(n = 31) 33.5 ± 11	(n = 23) 26.9 ± 15.4	(n = 54) 30.7 ± 13	(n = 33) 32 ± 14	NS
Male gender	23 (70)	16 (70)	39 (70)	21 (64)	NS
Deceased donor	21 (60)	21 (81)	42 (70)	24 ^c (71)	NS
First kidney transplant	31(88)	22 (85)	53 (87)	31 (91)	NS
Cold ischaemia time (min) ^b	(n = 26) 907 (70–1385)	(n = 25) 1245 (720–1860)	(n = 51) 1110 (84–1440)	(n = 29) 1020 (600–1320)	NS
Immunological features					
Full matched transplants	8 (26)	5 (22)	13 (24)	5 (16)	NS
HLA-A, -B, -DR mismatching (excluding full matched pairs) ^a	(n = 23) 2.8 ± 1.1	(n = 18) 2.8 ± 1.1	(n = 41) 2.8 ± 1.1	(n = 27) 3.2 ± 1	NS
HLA-DR mismatching (excluding full matched pairs) ^a	(n = 23) 1.2 ± 0.7	(n = 18) 0.6 ± 0.6	(n = 41) 0.7 ± 0.6	(n = 27) 0.9 ± 0.7	NS
Anti-HLA immunization prior transplantation (either positive PRA or anti-HLA antibodies)	7 (25)	11 (42)	18 (33)	11 (35)	NS
Anti-HLA immunization after transplantation (either positive PRA or anti-HLA antibodies; donor-specific, non-specific or undetermined)	1 (5)	12 (50)	13 (30)	3 (20)	NS
De novo donor-specific antibodies after transplantation	1 (5)	6 (28.6)	7 (17.1)	3 (20)	NS
Immunosuppression period					
IL-2 receptor antagonists	8 (23)	2 (8)	10 (17)	3 (9)	NS
Anti-lymphocyte globulins	9 (26)	9 (36)	18 (30)	9 (27)	NS
Other induction agents	0 (0)	3 (11)	3 (5)	4 (12)	NS
Steroids	34 (100)	25 (96)	60 (100)	34 (100)	
Tacrolimus	11 (32)	1 (4)	12 (20)	5 (15)	NS
Cyclosporine	22 (63)	15 (58)	37 (61)	23 (67)	NS
Mycophenolate acid derivatives	14 (41)	5 (19)	19 (32)	13 (39)	NS
Azathioprine	17 (50)	20 (77)	37 (62)	14 (42)	0.07
mTOR inhibitors	2 (6)	0	2 (3)	(n = 33) 0	NS
Cytomegalovirus seroconversion	2 (8)	(n = 18) 0	2 (5)	3 (13)	NS
Epstein–Barr virus seroconversion	2 (9)	4 (25)	6 (15.8)	3 (15)	NS
Patient with a history of cancer occurring during immunosuppression	4 (11)	10 (40)	14 (23)	27(79)	<0.0001
Post-transplant lymphoma disease	3	6	9	20	
Kaposi sarcoma	0	0	0	3	
Adenocarcinoma	0	3	3	4	
Skin cancer	1	5	6	5	
History of anticancer chemotherapy	2 (6)	4 (15)	6 (10)	19 (56)	<0.0001
History of rituximab use	1 (3)	3 (11)	4 (7)	7 (21)	0.05
Biopsy-proven acute rejection	3 (9)	5 (19)	8 (13)	5 (15)	NS
Immunosuppression exposure (months) ^b	(n = 35) 108 (58–156)	(n = 26) 128 (88–163)	(n = 61) 111 (65–161)	(n = 34) 141 (80–164)	NS

Continued

Table 1. Continued

	New TOL patients (N = 35)	Historic TOL patients (N = 26)	All TOL (N = 61)	MIS cohort (N = 34)	P-value for the comparison of all TOL versus MIS
Off-immunosuppression period					
Age at immunosuppression arrest (years) ^b	36 (29–47)	46 (31–57)	40 (31–52)	49 (35–62)	0.04
Cause of immunosuppressive withdrawal					<0.0001
Doctor driven for cancer	2 (6)	6 (23)	8 (13)	22 (81)	
Doctor driven for other reasons	1 (3)	1 (4)	2 (3)	3 (11)	
Patient driven	32 (91)	19 (73)	51 (84)	1 (4)	
Last good serum creatinine (last available before eventual degradation) (mg/dL) ^a	(n = 31) 1.35 (1.1–1.48)	(n = 26) 1.46 (1.12–1.63)	(57) 1.39 (1.11–1.6)	(n = 33) 1.23 (0.96–1.5)	0.08
Proteinuria > 300 mg and <1 g/day or g/g creatinine	9 (31)	15 (60)	24 (44)	10 (31)	NS
Period of optimal graft function without immunosuppressant (months) ^b	(n = 31) 70 (39–114)	(n = 26) 130 (69–172)	(n = 57) 92 (49–136)	(n = 33) 72 (30–123)	NS
Period of functioning transplant without immunosuppressant, irrespective of creatinine (months) ^b	77 (39–120)	153 (80–173)	107 (63–155)	78 (31–132)	0.09

Results from continuous variables are expressed as ^amean ± SD or ^bmedian (IQR); any missing data are indicated. Categorical data are expressed as number (%); any missing data can be deduced from numbers with their percentages.

^cOne combined kidney–pancreas transplantation.

NS designates non-significant P-values (≥0.05); however, all P-values ≤0.1 are mentioned.




FIGURE 3: Individual trajectories of TOL (A) and MIS (B) patients. White bars account for the duration, in months, of the tolerance period with a good kidney function [serum creatinine (S creat) <1.7 mg/dL and proteinuria (U prot) <1 g/day or g/g creatinine]. Dotted white bars account for the duration of tolerance with a less good kidney function (not meeting the above criteria) but free of dialysis. Coloured bars represent the occurrence of either end of tolerance because of immunosuppression resumption (for TOL patients) or increased dose (for MIS patients) (blue), back on dialysis (red) or patient death (black).

One out of 23 died with good graft function. A second group of four patients displayed suboptimal graft function (either serum creatinine or proteinuria above the limits), however, were stable for at least 1-year period without immunosuppressive medications. Their grafts survived for 60 (35–120) months. One out of four died with a functioning graft and another one required dialysis. The remaining two patients are still dialysis free. Lastly, a third group of eight patients lost their tolerant state after a period of 53 (36–77) months. Two of them were restarted on immunosuppressive medications for undefined graft injury (one haematuria and one glomerulopathy of unknown significance at biopsy) and the six others had a rising creatinine leading to dialysis in three. Their grafts had functioned with no treatment for 85 (45–127) months. Individual trajectories of TOL patients are depicted in Figure 3A.

New minimally immunosuppressed patients follow-up

Data on MIS patients covered a median period of 219 (160–287) months post-transplantation ($n = 34$). Among these 34 MIS patients, 27 were persistently almost tolerant at the time of data capture (see flow chart in Figure 2B). Almost tolerance status lasted 88 (32–99) months. Six other MIS patients

displayed good graft function on low-dose steroids for only 47 (32–99) months, after which one was restarted on a second immunosuppressive drug for a creeping increase in creatinine and five others had a declining graft function exceeding the limits described in the Materials and methods section. Overall, this cohort had functioning grafts for already 62 (44–146) months, while maintained on small doses of corticosteroids only. Finally, a single patient continued to maintain a functioning graft with a suboptimal serum creatinine (1.9 mg/dL at latest observation) 66 months after drug minimization. Individual trajectories of MIS patients are depicted in Figure 3B.

Patient and graft survival

As illustrated in Figure 4, 10-year patient survival after the establishment of operational tolerance and almost tolerance was 90% (95% CI: 75–96) and 59% (95% CI: 41–74), respectively. Death-censored graft survival at 10 years after the establishment of operational tolerance or almost tolerance was 87.1% (95% CI: 71.2–95.6) and 100% respectively. We did not directly compare TOL with MIS patients because those populations were different with regard to cancer incidence rates and other confounding factors.




FIGURE 4: (A) TOL patient survival. (B) TOL patient death-censored graft survival. (C) MIS patient survival. (D) MIS patient death-censored graft survival. TOL and MIS patients who returned on higher immunosuppressive drug levels before reaching death or graft loss were excluded from death-censored graft survival analysis (patients T11, 28, 32, 48 and 60; M7 and 8).

DISCUSSION

Here, we described 61 operationally tolerant and 34 almost tolerant kidney recipients at the same time. This unique, and likely the world's largest, data collection on tolerance in kidney transplantation should help draw more stable conclusions on those traits.

First, this study highlights that viral seroconversions, anti-HLA immunization, episodes of graft rejection and young age but also, history of autoimmune diseases were all conditions that were compatible with the later installation of operational tolerance. This is accumulating evidence that operational tolerance is acquired and specific and not the consequence of a generalized immune deficiency process [7, 22] and, notably, immunosenescence. The abundance of MIS patients displaying a good graft function years after cancer diagnosis and subsequent immunosuppression weaning also argues against a global immunodeficiency state.

Second, TOL and MIS patients demonstrated a prolonged death-censored graft survival and, for TOL patients only, a surprisingly long patient survival. European-wide data from the Collaborative Transplant Study report patient and death-censored graft survival for kidney patients below 75% at 10 years [23]. Although the cohorts are not comparable, it is striking that 85 and 100% of surviving TOL and MIS patients, respectively, had a functioning graft 10 years after immunosuppression weaning. For most of them, this represented >20 years of functioning graft. In line with this finding, a previous report [13] highlighted that, in 2004, eight out of nine kidney recipients with the world's longest graft survival were actually clinically tolerant. Seven of them still had good renal function after 39–40.5 years. Importantly, it is not clear whether the excellent patient and graft survival we observed were a consequence of immunosuppression minimization or whether some conditions associated with the development of operational tolerance (such as graft quality, recipient health or HLA matches) also confer a survival benefit, leading to a selection bias. In this regard, in the previous report on the 27 historical cases of operational tolerance [9], no clinical differences were found between TOL patients and the two matched groups of patients with stable graft function and those who rejected their graft after arrest of immunosuppression.

Third, the duration of operational tolerance and almost tolerance was, however, extremely variable. They are unstable phenotypes, which may be interrupted at any time, even after several years. Regarding historical cases of operational tolerance, we have previously stressed the wide disparities among operationally tolerant patients. Whereas some will virtually never develop any measurable immunological response towards the graft, others will mount immunological responses such as donor-specific antibodies, yet compatible with a prolonged allograft survival; finally, a third non-stable group will surreptitiously develop a damaging process that will end in graft loss in just a few years [12]. All these patients share the same designation of operational tolerance. There is thus a pressing need for reliable and clinically available biomarkers that go beyond binary criteria based on creatinine and/or proteinuria

levels. Several biomarkers have been proposed [10, 15, 17–19], but we still lack knowledge on their predictive and discriminative values based on prospective studies [20, 24].

We believe that the data presented here will be useful to confront phenotypic assumptions about those patients but also to support the development or the continuation of large networks dedicated to operational tolerance mechanistic studies (indices of tolerance, RISE, ITN: see summary at <http://www.kcl.ac.uk/lsm/research/divisions/timb/research/tolerance/index.aspx>). This study should also constitute an appeal to new clinicians to join our research efforts.

Patient dispersion is indeed a major obstacle for knowledge and research into operational tolerance [25]. Our strategy directly tackled this issue. The existence of a working group within the ERA-EDTA dedicated to transplantation (DESCARTES) and the interest of the Nantes hospital group for such patients for more than a decade provided a very helpful platform to access a high number of nephrologists across Europe. In particular, the personal contacts between the national coordinators and the local investigators were critical to this success.

Unfortunately, rare conditions also challenge the realization of prospective controlled studies. Most of the time, retrospective uncontrolled case analyses—typically registries—remain the most valuable research options [26]. As a consequence, systematic numbering of patients or prevalence could be difficult to assess, recruitment strategies could be biased and patient-related information could suffer lack of uniformity.

We reported 3 and 1.5 TOL and MIS patients per 10 000 kidney recipients, respectively. Of note, the cumulative incidence of operational tolerance described in this study is an approximation as it is difficult to accurately determine medication compliance/adherence. Detection of noncompliance relies on the patient's acknowledgement and, when available, on undetectable drug blood levels, prescription assistant software, and pharmacy repertoires or national security system records. Completing the required data for TOL or MIS patients is time-consuming, and some of our closest colleagues confessed to us not having found the time to report them. Finally, a lot of the centres were not able to reliably capture patients who may have temporarily fulfilled the criteria. It is likely, therefore, that the cumulative incidence of tolerant patients reported here is a minimum evaluation.

We acknowledge that unsystematic patient screening, absence of method uniformity in the biological tests reported and the lack of prospective biological and histological follow-up are limitations in this work. However, in the setting of a rare trait usually associated with noncompliance and patient concealment, this survey represents a valuable effort of not less than 145 kidney transplant practitioners across Europe. This survey brings further evidence that some transplant patients may spend prolonged periods without immunosuppressive drugs. We showed that operational tolerance was associated with excellent patient and graft outcomes, but not necessarily unlimited over time. As already stressed in the setting of experimental tolerance a long time ago [27], operational tolerance is also metastable in nature, not black or white, and 'every degree is represented'. This study, descriptive in nature, should help to set up or continue networks to support further clinical, immunological and molecular studies.

SUPPLEMENTARY DATA

Supplementary data are available online at <http://ndt.oxfordjournals.org>.

ACKNOWLEDGEMENTS

This survey was funded by the ERA-EDTA-DESCARTES working group, the Fonds Erasme (research grant), the Fonds Carine Vyghen, the Fonds Horlait-Dapsens, the RTRS Fondation de Coopération Scientifique CENTAURE and the IHU-Cesti project, which received French government financial support managed by the National Research Agency via the 'Investment Into The Future' program ANR-10-IBHU-005. J.Pascual is supported by FIS-FEDER PI13/00598 and REDINREN RD12/0021/0024. We are also very indebted to the colleagues who replied to the survey: Albania: M. Barbullushi, A. Idrizi, University Hospital Center Mother Teresa, Tirana. Austria: G. Mayer, Medical University, Innsbruck; A. Rosenkranz, Medical University, Graz. Belgium: J. Sennesael, BBTP, Brussels; J.-L. Bosmans, University Hospital, Antwerpen; M. De Meyer, Cliniques universitaires Saint Luc UCL, Brussels; S. Van Laecke, University Hospital, Ghent. Bosnia and Herzegovina: E. Mesic, University Hospital, Tuzla; H. Resic, University Hospital, Sarajevo. Croatia: N. Basic Jukic, University Hospital, Zagreb; M. Knotek, University Hospital Merkur, Zagreb. Czech Republic: T. Seeman, Department of Pediatrics, University Hospital Motol, Prague; P. Navratil, University Hospital, Hradec Kralove; J. Dedochova, University Hospital, Ostrava; K. Krejci, University Hospital, Olomouc. Denmark: K. Skov, University Hospital, Aarhus; C. Bistrup, University Hospital, Odense. France: C. Presne, Hopital Sud CHU Amiens, Amiens; R. Joannides, Hopital de Bois Guillaume CHU Rouen, Bois Guillaume; P. Grise, D. Guerrot, I. Etienne, M. Hanoy, M. Godin, and B. Legallier, Hopital de Bois Guillaume CHU Rouen, Bois Guillaume; P. Merville, CHU Pellegrin, Bordeaux; G. Robert, CHU de Bordeaux, Bordeaux; J.-P. Boiteux and P. Deteix, CHU Hopital G. Montpied, Clermont Ferrand; V. Audard, S. Homs, T. Kofman and P. Lang, Hopital Henri Mondor (Ap Hp), Creteil; B. Charpentier, Hopital de Bicetre (Ap Hp), Le Kremlin Bicetre; M. Dehennault, R. Novo and Ch. Samaille, Hop Jeanne de Flandre Chr Lille, Lille; J.-P. Rerolle, CHU Dupuytren Limoges, Limoges; Y. Berland, P. Brunet, N. Jourde Chiche, E. Lechevallier, Ch. Maurin, V. Moal, R. Purcus and H. Vacher Coponat, Hopital de la Conception, Marseille 5eme; L. Cabaniols, T. Murez and G. Poinas, Hopital Lapeyronie CHU Montpellier; G. Favre, A. Jeribi and O. Moranne, Hopital Pasteur, Nice; I. Jollet, Efs Centre Atlantique, Poitiers; E. Verdier, CHU la Miletrie, Poitiers; T. Frouget, P. Le Pogamp, J. Rivalan and C. Vigneau, C. H. R. Pontchaillou Rennes, Rennes; Y. Georg and P. Wolf, CHU de Strasbourg/Nouvel Hopital Civil, Strasbourg. Germany: M. Wiesener, University Hospital, Erlangen; W. Arns, Merheim Medical Center, Cologne; T. Rath, Westpfalz-Klinikum, Kaiserslautern; M. Nitschke, University Hospital Schleswig-Holstein, Lübeck; U. Kunzendorf, University Hospital Schleswig-Holstein,

Kiel; B. Banas, University Hospital, Regensburg; M. van der Giet, Charité-Campus Benjamin Franklin, Berlin; C. Schinköthe, University Hospital, Jena; O. Hakenberg, Universitätsmedizin, Rostock; B. Krämer, Transplant Centre, Mannheim; R. Weimer, Internal Medicine/Nephrology, Gießen; M. Haubitz, Nephrologie, Klinikum Fulda; W. Gwinner, Medical School, Hannover. Greece: J. Boletis, Laiko University Hospital, Athens; K. Siamopoulos, University Hospital, Ioannin. Ireland: P. J. Conlon, Beaumont Hospital, Dublin. Israel: Y. Frishberg, Shaare Zedek Medical Center, Jerusalem. Norway: A. Varberg Reisæter, Oslo University Hospital – Rikshospitalet. Poland: M. Krajewska, Medical University, Wroclaw; M. Nowicki, Medical University, Lodz; A. Dębska-Ślizień, Transplant Centre, Gdańsk; M. Durlik, Transplant Centre, Warsaw. Portugal: D. Machado, Hosp Santa Cruz, Carnaxide. Serbia: R. Naumovic, Clinic of Nephrology, Clinical Center of Serbia, Belgrade. Slovakia: Z. Zilinska, University Hospital, Bratislava; E. Lackova, University Hospital, Banska Bystrica; I. Dedinska, University Hospital, Martin. Spain: C. Jiménez, Hospital Universitario La Paz, Madrid; D. Marrero, Hospital Universitario de Canarias, Tenerife; J. Portoles, Hospital Puerta de Hierro, Madrid; E. Gavela, Hospital Doctor Peset, Valencia; E. Rodrigo, Hospital U.M.V., Santander; L. Guirado, Fundacio Puigvert, Barcelona; J. J. Cubero Gómez, Hospital Infanta Cristina, Badajoz; R. G. Agudo, La Mancha-Centro Hospital Complex, Alcázar de San Juan; M. L. Rodríguez Ferrero, Hospital General Universitario Gregorio Marañón, Madrid; G. Tabernero Fernández, Hospital Universitario de Salamanca; A. Osuna, Virgen Nieves Hospital, Granada; A. Mazuecos, Hospital Puerta del Mar, Cádiz; R. Sanchez Hernandez, Hospital General de Segovia, Segovia; M. Velo, Alcalá de Henares, Madrid; O. Gracia, Hospital de Alcañiz, Teruel; M^a D. del Pino, Complejo Hospitalario Torrecardenas, Almería; A. Vila Santandreu, Hospital Sant Joan de Deu, Esplugues de Llobregat; S. Cigarrán Hospital Da Costa, Burela; J. Martins Muñoz, Hospital Universitario de Getafe, Madrid; G. de Arriba, Hospital Universitario de Guadalajara, Guadalajara; K. Toledo, José Molina Orosa, Arrecife, Lanzarote; M. Martin, Hospital Arnau de Vilanova, Lleida; J. Ocaña, Hospital Universitario Fundación Alcorcón, Madrid. Switzerland: J. Steiger, University Hospital, Basel; I. Binet, Cantonal Hospital, St Gallen. The Netherlands: S.A. Nurmohamed, VU University medical center, Amsterdam; R.C. Bakker, Amphia Hospital, Breda; M. H. L. Christiaans, University Medical Centre, Maastricht; E. Scholten, MC Haaglanden, Den Haag.

CONFLICT OF INTEREST STATEMENT

None declared.

REFERENCES

1. Snyder JJ, Israni AK, Peng Y *et al*. Rates of first infection following kidney transplant in the United States. *Kidney Int* 2009; 75: 317–326
2. Farrugia D, Mahboob S, Cheshire J *et al*. Malignancy-related mortality following kidney transplantation is common. *Kidney Int* 2014; 85: 1395–1403
3. Ghisdal L, Van Laecke S, Abramowicz MJ *et al*. New-onset diabetes after renal transplantation: risk assessment and management. *Diabetes Care* 2012; 35: 181–188

4. Pascual M, Theruvath T, Kawai T *et al*. Strategies to improve long-term outcomes after renal transplantation. *N Engl J Med* 2002; 346: 580–590
5. Scandling JD, Busque S, Dejbakhsh-Jones S *et al*. Tolerance and chimerism after renal and hematopoietic-cell transplantation. *N Engl J Med* 2008; 358: 362–368
6. Kawai T, Cosimi AB, Spitzer TR *et al*. HLA-mismatched renal transplantation without maintenance immunosuppression. *N Engl J Med* 2008; 358: 353–361
7. Roussey-Kesler G, Giral M, Moreau A *et al*. Clinical operational tolerance after kidney transplantation. *Am J Transplant* 2006; 6: 736–746
8. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. *Am J Transplant* 2006; 6: 1774–1780
9. Brouard S, Pallier A, Renaudin K *et al*. The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases. *Am J Transplant* 2012; 12: 3296–3307
10. Newell KA, Asare A, Kirk AD *et al*. Identification of a B cell signature associated with renal transplant tolerance in humans. *J Clin Invest* 2010; 120: 1836–1847
11. Newell KA. Clinical transplantation tolerance. *Semin Immunopathol* 2011; 33: 91–104
12. Soullillou JP, Giral M, Brouard S. Operational tolerance in kidney transplantation-improved terminology may enable more precise investigation. *Transplantation* 2013; 96: e36–e38
13. Starzl TE, Murase N, Demetris AJ *et al*. Lessons of organ-induced tolerance learned from historical clinical experience. *Transplantation* 2004; 77: 926–929
14. Zoller KM, Cho SI, Cohen JJ *et al*. Cessation of immunosuppressive therapy after successful transplantation: a national survey. *Kidney Int* 1980; 18: 110–114
15. Sagoo P, Perucha E, Sawitzki B *et al*. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. *J Clin Invest* 2010; 120: 1848–1861
16. Berlanda M, Di Cocco P, Mazzotta C *et al*. Clinical operational tolerance after kidney transplantation: a short literature review. *Transplant Proc* 2008; 40: 1847–1851
17. Brouard S, Mansfield E, Braud C *et al*. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. *Proc Natl Acad Sci USA* 2007; 104: 15448–15453
18. Roedder S, Li L, Alonso MN *et al*. A three-gene assay for monitoring immune quiescence in kidney transplantation. *J Am Soc Nephrol* 2015; 26: 2042–2053
19. Baron D, Ramstein G, Chesneau M *et al*. A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft. *Kidney Int* 2015; 87: 984–995
20. Girmanova E, Hrubá P, Viklický O. Circulating biomarkers of tolerance. *Transplant Rev (Orlando)* 2015; 29: 68–72
21. Snanoudj R, Tinel C, Legendre C. Immunological risks of minimization strategies. *Transpl Int* 2015; 28: 901–910
22. Ballet C, Roussey-Kesler G, Aubin JT *et al*. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. *Am J Transplant* 2006; 6: 2796–2801
23. <http://www.ctstransplant.org/public/policy.shtml>, K-15102 and K-15107, 17 April 2015, date last accessed
24. Baron D, Giral M, Brouard S. Reconsidering the detection of tolerance to individualize immunosuppression minimization and to improve long-term kidney graft outcomes. *Transpl Int* 2015; 28: 938–959
25. Devuyt O, Knoers NV, Remuzzi G *et al*. Rare inherited kidney diseases: challenges, opportunities, and perspectives. *Lancet* 2014; 383: 1844–1859
26. Kelly RJ, Hochsmann B, Szer J *et al*. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. *N Engl J Med* 2015; 373: 1032–1039
27. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. *Nature* 1953; 172: 603–606

Received for publication: 23.9.2015; Accepted in revised form: 29.11.2015